Our Approach
Core Pillars of Astatine Drug Innovation
Our pillars reflect our commitment to turning breakthrough science into treatments that truly reach people. With Patient-centric, Differentiated Pipeline, Reliable Supply, Empowering Clinical Development, and Scalable Future, we strive to ensure that the promise of Astatine innovation becomes real-world therapies for patients and families.
Feature 1
Patient-centric
Maximizing efficacy
By aligning biological and physical half-lives, we aim to fully leverage alpha radiation’s therapeutic power potential.
Reducing side effects
Using the “one decay = one alpha” property without multiple daughter nuclides, we pursue selective tumor targeting with lower toxicity.
Outpatient feasibility
With minimal radiation risk to families and caregivers, we aim to make alpha therapy accessible as an outpatient option.
Feature 2
Differentiated Pipeline
Covalent labeling without chelators
211At can be directly bonded to small molecules, enabling new approaches that reach beyond the surface to intracellular targets.
Quality assurance advantages
Its simple decay cascade avoids multiple isotopes in formulation, allowing clearer quality control and regulatory explanation.
Broad applicability
By coupling 211At with tumor-specific targeting ligands, studies suggest applicability across diverse cancers, including rare types.
Feature 3
Reliable Supply
Sustainable isotope production
211At is produced from readily available 209Bi using mid-size cyclotrons, ensuring a sustainable and independent supply.
Proven clinical readiness
Dozens of successful GMP batches and clinical administrations demonstrate a reliable, trial-ready supply chain.
Established domestic network
Partnerships with Japanese cyclotron facilities and Kobe City Medical Center secureseamless investigational drug delivery.
Feature 4
Empowering Clinical Development
Pioneering clinical experience
Collaborations with world-leading universities and investigators have built valuable know-how for advancing 211At into human studies.
Agile development team
Clinical entry experts rapidly advance candidates from discovery through IND-enabling and CMC development to clinical trials.
Regulatory communication
Close communication with pharmaceutical and nuclear authorities ensures smooth translation from research to clinic.
Feature 5
Scalable Future
Decentralized supply model
A network of small- and medium-sized cyclotrons with GMP facilities enables stable, risk-diversified isotope supply.
Global expansion outlook
With Europe and North America in scope, we aim to establish a reproducible global supply and development model.
From clinical to commercial
Building on investigational drug supply experience, the system is designed to evolve toward consistent commercial availability.